Myriad Genetics
MYGN
264 hedge funds and large institutions have $2.22B invested in Myriad Genetics in 2018 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 110 increasing their positions, 74 reducing their positions, and 50 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 74
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.23% less ownership
Funds ownership: 106.52% → 102.29% (-4.2%)
7% less funds holding
Funds holding: 284 → 264 (-20)
36% less capital invested
Capital invested by funds: $3.48B → $2.22B (-$1.26B)
38% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 50
57% less call options, than puts
Call options by funds: $2.43M | Put options by funds: $5.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$28.8M |
| 2 |
BlackRock
New York
|
+$26.5M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$26M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$23.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$83.4M |
| 2 |
Millennium Management
New York
|
-$22.1M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$18.9M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$12.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.91M |
MYGN Hedge Fund Activity: Q4 2018 in Review
264 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2018, worth a combined $2.22B — down 36% from $3.48B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of MYGN and 31 opened new positions — a net loss of 19 holders — while 74 trimmed existing stakes and 110 added.
The largest buyer was Rice Hall James & Associates, opening a new position worth an estimated $28.8M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $83.4M.
- 264 institutional investors held Myriad Genetics (MYGN) as of Q4 2018, down from 284 in Q3 2018.
- Funds reported $2.22B of Myriad Genetics stock for Q4 2018, down 36% quarter-over-quarter.
- 31 funds opened new Myriad Genetics positions in Q4 2018 and 50 closed out, a net change of -19 holders.
- The largest Myriad Genetics buyer in Q4 2018 was Rice Hall James & Associates, an estimated $28.8M added.
- The largest Myriad Genetics seller in Q4 2018 was Thrivent Financial for Lutherans, an estimated $83.4M sold.
Based on aggregated 13F filings for Q4 2018.